
<DOC>
<DOCNO>
WSJ901224-0081
</DOCNO>
<DOCID>
901224-0081.
</DOCID>
<HL>
   Technology:
   Synergen Inc. Offering
</HL>
<DATE>
12/24/90
</DATE>
<SO>
WALL STREET JOURNAL (J), NO PAGE CITATION
</SO>
<CO>
   SYGN
</CO>
<IN>
MEDICAL AND BIOTECHNOLOGY (MTC)
STOCK MARKET, OFFERINGS (STK)
</IN>
<LP>
   BOULDER, Colo. -- Synergen Inc. said it expects to raise
$50 million in an offering of partnership units to finance
research and development of a potential treatment for
inflammatory diseases such as rheumatoid arthritis.
   The biotechnology concern said the partnership units will
own certain rights to the treatment, interleukin-1 receptor
antagonist, which is currently in human clinical trials.
</LP>
<TEXT>
   The company said it expects the partnership to be funded
in the first quarter of 1991.
</TEXT>
</DOC>